speb/financial-data huggingface dataset:
Financial ratios for SCOR — annual report dated 2022-12-31
Total revenue: 376423000
Gross profit: 171129000
Operating income: -22607000
Net income: -66561000
Capital expenditures: 1137000
Operating cash flow: 34937000
Depreciation & amortization: 46288000
Net tangible assets: -257138000
Owner earnings: -21410000
Buffett classification: The Gruesome
Stock price: 23.2
Shares outstanding: 15093696
Book value: 144162000
P/B ratio: 2.4290294751737624
Market cap (USD): 350173747.2
Debt to equity: 0.36921657579667316
Current ratio: 0.6349286151274146
Quick ratio: 0.6349286151274146
Interest coverage ratio: -24.707103825136613
COGS to revenue (%): 54.53811270830954
R&D to revenue (%): 9.82591393193296
SG&A to revenue (%): 34.443431990075
Free cash flow (dilution-adjusted): 8937000
Buyback yield (%): 0
Retained earnings: -1300789000
Receivables turnover: 5.498678002249587
Capitalized R&D asset: 36987000
ROCI (R&D-adjusted, %): 0.45327769944439783
FCF margin (%): 2.3741907375479183
Rule of 40 score: 2.3741907375479183
Financial ratios for SCOR — annual report dated 2023-12-31
Total revenue: 371343000
Gross profit: 165763000
Operating income: 12335000
Net income: -79361000
Capital expenditures: 1580000
Operating cash flow: 28926000
Depreciation & amortization: 26920000
Net tangible assets: -262372000
Owner earnings: -54021000
Capex to operating income (%): 12.809079854073774
Buffett classification: The Great
Stock price: 16.7
Shares outstanding: 15093696
Book value: 56103000
P/B ratio: 4.4928920592481685
Market cap (USD): 252064723.2
Debt to equity: 0.8374774967470545
Current ratio: 0.5367520992983167
Quick ratio: 0.5367520992983167
Interest coverage ratio: 8.536332179930795
COGS to revenue (%): 55.3612159108964
R&D to revenue (%): 9.075436994907674
SG&A to revenue (%): 30.837796861661595
Free cash flow (dilution-adjusted): 605000
Buyback yield (%): 0
Retained earnings: -1396420000
Receivables turnover: 5.8180522044307965
Capitalized R&D asset: 58482290
ROCI (R&D-adjusted, %): 6.119917319935162
Rosenberg metric: -0.14507800037851137
FCF margin (%): 0.16292215014151337
Revenue growth (%): -1.3495455909973622
Rule of 40 score: -1.1866234408558487
Financial ratios for SCOR — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 6.79
Shares outstanding: 15093696
Market cap (USD): 102486195.84
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SCOR — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 5.84
Shares outstanding: 15093696
Market cap (USD): 88147184.64
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SCOR — annual report dated 2024-12-31
Total revenue: 356047000
Gross profit: 147339000
Operating income: 5915000
Net income: -60248000
Capital expenditures: 813000
Operating cash flow: 18104000
Depreciation & amortization: 28795000
Net tangible assets: -259331000
Owner earnings: -32266000
Capex to operating income (%): 13.7447168216399
Buffett classification: The Great
Stock price: 5.84
Shares outstanding: 15093696
Book value: -8263000
Market cap (USD): 88147184.64
Debt to equity: -7.760014522570495
Current ratio: 0.8229528422591847
Quick ratio: 0.8229528422591847
Interest coverage ratio: 3.141263940520446
COGS to revenue (%): 58.61810378966822
R&D to revenue (%): 9.286976157642108
SG&A to revenue (%): 29.575028015964183
Free cash flow (dilution-adjusted): -9149000
Buyback yield (%): 0
Retained earnings: -1474268000
Receivables turnover: 5.5402078859739206
Capitalized R&D asset: 67851380
ROCI (R&D-adjusted, %): 1.1985825228111007
Rosenberg metric: -0.54669000919854
FCF margin (%): -2.5696045746769385
Revenue growth (%): -4.1191028240737
Rule of 40 score: -6.688707398750639
Financial ratios for SCOR — quarterly report dated 2025-03-31
Total revenue: 85709000
Gross profit: 33962000
Operating income: -2066000
Net income: -3993000
Capital expenditures: 379000
Operating cash flow: 9062000
Depreciation & amortization: 7346000
Net tangible assets: -264833000
Owner earnings: 2974000
Buffett classification: The Gruesome
Stock price: 6.87
Shares outstanding: 15093696
Book value: -13458000
Market cap (USD): 103693691.52
Debt to equity: -4.595407935800267
Current ratio: 0.7388973508944837
Quick ratio: 0.7388973508944837
Interest coverage ratio: -1.1751990898748579
COGS to revenue (%): 60.37522313876023
R&D to revenue (%): 9.47158408101833
SG&A to revenue (%): 31.82629595491722
Free cash flow (dilution-adjusted): 2673000
Buyback yield (%): 0
Retained earnings: -1482700000
Receivables turnover: 1.6935525301823786
Capitalized R&D asset: 8118000
ROCI (R&D-adjusted, %): 1.1314871989097686
FCF margin (%): 3.118692319359694
Rule of 40 score: 3.118692319359694
Financial ratios for SCOR — quarterly report dated 2025-06-30
Total revenue: 89389000
Gross profit: 36290000
Operating income: -1681000
Net income: -9492000
Capital expenditures: 145000
Operating cash flow: 932000
Depreciation & amortization: 7449000
Net tangible assets: -273929000
Owner earnings: -2188000
Buffett classification: The Gruesome
Stock price: 4.82
Shares outstanding: 15093696
Book value: -21669000
Market cap (USD): 72751614.72
Debt to equity: -2.7481655821680744
Current ratio: 0.6899904139184182
Quick ratio: 0.6899904139184182
Interest coverage ratio: -1.0824211204121057
COGS to revenue (%): 59.40216357717393
R&D to revenue (%): 8.730380695611316
SG&A to revenue (%): 33.04097819642238
Free cash flow (dilution-adjusted): -6557000
Buyback yield (%): 0
Retained earnings: -1496686000
Receivables turnover: 1.6419124940303442
Capitalized R&D asset: 13243060
ROCI (R&D-adjusted, %): 0.2819029655201224
Rosenberg metric: 0.286770140428677
FCF margin (%): -7.335354461958407
Revenue growth (%): 4.293598105216488
Rule of 40 score: -3.041756356741919
Financial ratios for SCOR — quarterly report dated 2025-09-30
Total revenue: 88906000
Gross profit: 36123000
Operating income: 1705000
Net income: 453000
Capital expenditures: 125000
Operating cash flow: 9495000
Depreciation & amortization: 7546000
Net tangible assets: -277921000
Owner earnings: 7874000
Return on net tangible assets (%): -2.8331792127978814
Capex to operating income (%): 7.331378299120235
Buffett classification: The Great
Stock price: 8.73
P/E ratio: 72.7196280794702
Shares outstanding: 15093696
Book value: -26257000
Market cap (USD): 131767966.08000001
Debt to equity: -2.1596145789694177
Current ratio: 0.6463044307283795
Quick ratio: 0.6463044307283795
Effective tax rate (%): -219.01408450704224
Interest coverage ratio: 1.003531489111242
COGS to revenue (%): 59.36944638157154
R&D to revenue (%): 8.080444514430972
SG&A to revenue (%): 29.920365329674038
Free cash flow (dilution-adjusted): 3104000
Buyback yield (%): 0
Retained earnings: -1501204000
Receivables turnover: 1.7573134092346616
Capitalized R&D asset: 15091620
ROCI (R&D-adjusted, %): 0.4232715632613406
Rosenberg metric: -0.021399282419272168
FCF margin (%): 3.4913279193755207
Revenue growth (%): -0.5403349405407825
Rule of 40 score: 2.950992978834738
Financial ratios for SCOR — quarterly report dated 2025-12-31
Total revenue: 93465000
Gross profit: 38333000
Operating income: 6551000
Net income: 49505000
Capital expenditures: 307000
Operating cash flow: 3247000
Depreciation & amortization: 7646000
Net tangible assets: -139726000
Owner earnings: 56844000
Return on net tangible assets (%): -40.68247856519188
Capex to operating income (%): 4.686307433979545
Buffett classification: The Great
Stock price: 6.5
P/E ratio: 2.689908260905327
Shares outstanding: 15093696
Book value: 111439000
P/B ratio: 0.8803832051615682
Market cap (USD): 98109024
Debt to equity: 0.4874236129182782
Current ratio: 0.7833771390907389
Quick ratio: 0.7833771390907389
Effective tax rate (%): 30.962152302781575
Interest coverage ratio: 3.8924539512774805
COGS to revenue (%): 58.98678649761943
R&D to revenue (%): 7.5621890547263675
SG&A to revenue (%): 25.76579468250147
Free cash flow (dilution-adjusted): -2526000
Buyback yield (%): 0
Retained earnings: -1429995000
Receivables turnover: 1.6322913028292
Capitalized R&D asset: 14456600
ROCI (R&D-adjusted, %): 2.094063445411004
Rosenberg metric: 0.30762806236080176
FCF margin (%): -2.7026159524955866
Revenue growth (%): 5.1278878815827955
Rule of 40 score: 2.425271929087209
Financial ratios for SCOR — annual report dated 2025-12-31
Total revenue: 357469000
Gross profit: 144708000
Operating income: 4509000
Net income: 22569000
Capital expenditures: 956000
Operating cash flow: 22736000
Depreciation & amortization: 29987000
Net tangible assets: -139726000
Owner earnings: 51600000
Return on net tangible assets (%): -36.92941900576843
Capex to operating income (%): 21.20204036371701
Buffett classification: The Great
Stock price: 6.5
P/E ratio: 4.347070051841021
Shares outstanding: 15093696
Book value: 111439000
P/B ratio: 0.8803832051615682
Market cap (USD): 98109024
Debt to equity: 0.4874236129182782
Current ratio: 0.7833771390907389
Quick ratio: 0.7833771390907389
Interest coverage ratio: 0.6736889287315105
COGS to revenue (%): 59.51872749804878
R&D to revenue (%): 8.44101166814465
SG&A to revenue (%): 30.07141878036977
Free cash flow (dilution-adjusted): -3306000
Buyback yield (%): 0
Retained earnings: -1429995000
Receivables turnover: 6.2429095354523225
Capitalized R&D asset: 63449550
ROCI (R&D-adjusted, %): 0.6803198671060029
Rosenberg metric: -0.079568136454364
FCF margin (%): -0.9248354402759401
Revenue growth (%): 0.3993854743896171
Rule of 40 score: -0.525449965886323
Financial ratios for SKN.AX — annual report dated 2021-06-30
Total revenue: 217098.4962406015
Gross profit: 143187.21804511276
Operating income: -3077742.857142857
Net income: -2287611.2781954887
Capital expenditures: 27375.939849624057
Depreciation & amortization: 303690.22556390974
Net tangible assets: 986785.7142857142
Owner earnings: -2011296.9924812028
Return on net tangible assets (%): -203.82307560432022
Buffett classification: The Gruesome
Stock price: 0.06766917293233082
Shares outstanding: 3491334115
Book value: 7242083.458646616
P/B ratio: 32.62261382950593
Market cap (USD): 236255691.9924812
Debt to equity: 0.0032174100191954486
Current ratio: 3.6056437535258494
Quick ratio: 3.3086408583380345
Interest coverage ratio: -45.927183376716634
COGS to revenue (%): 34.0450438282059
R&D to revenue (%): 678.2805351508791
SG&A to revenue (%): 319.44199126552866
Free cash flow (dilution-adjusted): -2058691.7293233082
Buyback yield (%): 0
Retained earnings: -8622008.270676691
Inventory turnover: 0.4403718221525367
Receivables turnover: 0.2571407198027235
Capitalized R&D asset: 1472536.8421052631
ROCI (R&D-adjusted, %): -21.889326496777716
FCF margin (%): -948.2754440831056
Rule of 40 score: -948.2754440831056
Financial ratios for SKN.AX — annual report dated 2022-06-30
Total revenue: 971262.0689655172
Gross profit: 719417.9310344828
Operating income: -2398898.620689655
Net income: -1118819.3103448276
Capital expenditures: 0
Depreciation & amortization: 280120
Net tangible assets: 1605515.1724137932
Owner earnings: -838699.3103448276
Return on net tangible assets (%): -52.23864120099812
Buffett classification: The Gruesome
Stock price: 0.013793103448275864
Shares outstanding: 3491334115
Book value: 7486902.758620691
P/B ratio: 6.432076677534074
Market cap (USD): 48156332.62068966
Debt to equity: 0.0022594859676332247
Current ratio: 4.094846854152978
Quick ratio: 3.9064233562378328
Interest coverage ratio: -260.2621025065469
COGS to revenue (%): 25.929576164677314
R&D to revenue (%): 143.73300291835008
SG&A to revenue (%): 125.25537338549914
Free cash flow (dilution-adjusted): -1033201.3793103448
Buyback yield (%): 0.20255867147220882
Retained earnings: -9027282.068965517
Inventory turnover: 2.3670482388477643
Receivables turnover: 1.0371443384304495
Capitalized R&D asset: 2382623.8221415607
ROCI (R&D-adjusted, %): -19.27514897633836
Rosenberg metric: 0.3913183674002627
FCF margin (%): -106.37719852591367
Revenue growth (%): 347.38313981185144
Rule of 40 score: 241.00594128593775
Financial ratios for SKN.AX — annual report dated 2023-06-30
Total revenue: 128563.5761589404
Gross profit: 62991.39072847682
Operating income: -3345290.728476821
Net income: -2718009.9337748345
Capital expenditures: 0
Depreciation & amortization: 268989.4039735099
Net tangible assets: 400531.7880794702
Owner earnings: -2449020.5298013245
Return on net tangible assets (%): -611.4422382164109
Buffett classification: The Gruesome
Stock price: 0.006622516556291391
Shares outstanding: 3491334115
Book value: 5360790.0662251655
P/B ratio: 4.313061637277198
Market cap (USD): 23121417.98013245
Debt to equity: 0.002193014694755011
Current ratio: 1.545867364724354
Quick ratio: 1.4683391325011999
Interest coverage ratio: -86.71614708507862
COGS to revenue (%): 51.003703684625336
R&D to revenue (%): 870.6770170657958
SG&A to revenue (%): 540.7219866997027
Free cash flow (dilution-adjusted): -1215848.3443708608
Buyback yield (%): 0.37188362878870446
Retained earnings: -11359189.40397351
Inventory turnover: 1.1809171685848887
Receivables turnover: 0.16559331113264456
Capitalized R&D asset: 2540646.840242305
ROCI (R&D-adjusted, %): -44.99471118081975
Rosenberg metric: -0.47021145442288503
FCF margin (%): -945.7175824572067
Revenue growth (%): -86.76324544457168
Rule of 40 score: -1032.4808279017784
Financial ratios for SKN.AX — annual report dated 2024-06-30
Total revenue: 277468
Gross profit: 241249.33333333334
Operating income: -2184387.3333333335
Net income: -1249202.6666666667
Capital expenditures: 0
Depreciation & amortization: 4062.6666666666665
Net tangible assets: -689183.3333333334
Owner earnings: -1245140
Buffett classification: The Gruesome
Stock price: 0
Shares outstanding: 3491334115
Book value: -699148
Market cap (USD): 0
Debt to equity: -0.028505171055818415
Current ratio: 0.41341607351838705
Quick ratio: 0.39571013263918287
Interest coverage ratio: -40.0310442144873
COGS to revenue (%): 13.053277014526598
R&D to revenue (%): 597.7277860269772
SG&A to revenue (%): 133.93015891322003
Free cash flow (dilution-adjusted): -168080
Retained earnings: -17558768.666666668
Inventory turnover: 1.7026451046759432
Receivables turnover: 0.7677530510750704
Capitalized R&D asset: 2869171.550506204
ROCI (R&D-adjusted, %): -88.34854933343115
Rosenberg metric: 0.1592479552382857
FCF margin (%): -60.57635475081812
Revenue growth (%): 115.82162560332972
Rule of 40 score: 55.2452708525116
Financial ratios for SST.AX — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 6.3188405797101455
Shares outstanding: 31008000
Market cap (USD): 195934608.6956522
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SST.AX — annual report dated 2022-12-31
Total revenue: 42793243.24324325
Gross profit: -33779054.05405405
Operating income: -311052702.7027027
Net income: 40162837.83783784
Capital expenditures: 87264864.86486487
Depreciation & amortization: 64377702.7027027
Net tangible assets: 1268212162.162162
Owner earnings: 17275675.675675675
Return on net tangible assets (%): 1.3622070652770393
Buffett classification: The Gruesome
Stock price: 6.439189189189189
P/E ratio: 4.971421072996753
Shares outstanding: 31008000
Book value: 674927027.027027
P/B ratio: 0.29583402409870135
Market cap (USD): 199666378.37837836
Debt to equity: 0.5836647004881409
Current ratio: 0.45488847907855284
Quick ratio: 0.3700219598044638
Effective tax rate (%): 30.94198015660943
Interest coverage ratio: -391.7940425531915
COGS to revenue (%): 178.93548488963273
SG&A to revenue (%): 235.08226229197584
Free cash flow (dilution-adjusted): 36734459.45945946
Buyback yield (%): 0
Retained earnings: 677574324.3243244
Inventory turnover: 1.9907775006148334
Receivables turnover: 0.38331043581937796
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -40.32328137426993
FCF margin (%): 85.8417279818107
Rule of 40 score: 85.8417279818107
Financial ratios for SST.AX — annual report dated 2023-12-31
Total revenue: 366390410.95890415
Gross profit: 275308904.10958904
Operating income: -38089726.02739726
Net income: 40182876.71232877
Capital expenditures: 148218493.15068492
Depreciation & amortization: 71595205.47945206
Net tangible assets: 1320632876.712329
Owner earnings: -36440410.95890409
Return on net tangible assets (%): -2.7593142349765865
Buffett classification: The Gruesome
Stock price: 8.082191780821919
P/E ratio: 6.236800927267459
Shares outstanding: 31008000
Book value: 609056849.3150685
P/B ratio: 0.41147653625693453
Market cap (USD): 250612602.73972607
Debt to equity: 1.0078731656738524
Current ratio: 1.4321971544878
Quick ratio: 1.1164556658322604
Effective tax rate (%): 30.4802758653379
Interest coverage ratio: -33.662832929782084
COGS to revenue (%): 24.85914044828295
SG&A to revenue (%): 32.62669882040641
Free cash flow (dilution-adjusted): -73585616.43835616
Buyback yield (%): 0
Retained earnings: 704380136.9863014
Inventory turnover: 1.684131205673759
Receivables turnover: 2.3102935968420417
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -3.149824386712862
FCF margin (%): -20.083936215953486
Revenue growth (%): 756.1875267931571
Rule of 40 score: 736.1035905772036
Financial ratios for SST.AX — annual report dated 2024-12-31
Total revenue: 43697515.52795031
Gross profit: -54718633.54037267
Operating income: -377187577.63975155
Net income: 29187577.63975155
Capital expenditures: 134845341.61490682
Depreciation & amortization: 70477018.63354036
Net tangible assets: 615522981.3664596
Owner earnings: -35180745.3416149
Return on net tangible assets (%): -5.715585998676073
Buffett classification: The Gruesome
Stock price: 8.267080745341614
P/E ratio: 8.782696629213484
Shares outstanding: 31008000
Book value: 673865217.3913043
P/B ratio: 0.38041084943355424
Market cap (USD): 256345639.75155276
Debt to equity: 0.4352253570069028
Current ratio: 1.1270507715505955
Quick ratio: 0.9145335030834937
Effective tax rate (%): 32.30866740611631
Interest coverage ratio: -30.791603285670828
COGS to revenue (%): 225.22138359416087
SG&A to revenue (%): 282.76263983056873
Free cash flow (dilution-adjusted): -46300000
Buyback yield (%): 0
Retained earnings: 647965838.5093167
Inventory turnover: 3.3660484778960336
Receivables turnover: 0.49190678291999074
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): -38.950413382165245
FCF margin (%): -105.95568063906302
Revenue growth (%): -88.07351005350094
Rule of 40 score: -194.02919069256396
Financial ratios for SST.AX — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 615522981.3664596
Buffett classification: The Gruesome
Stock price: 8.267080745341614
Shares outstanding: 31008000
Book value: 673865217.3913043
P/B ratio: 0.38041084943355424
Market cap (USD): 256345639.75155276
Debt to equity: 0.4352253570069028
Current ratio: 1.1270507715505955
Quick ratio: 0.9145335030834937
Buyback yield (%): 0
Retained earnings: 647965838.5093167
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for STGN.SW — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 43.25274725274725
Shares outstanding: 5463121
Market cap (USD): 236294991.8241758
Buyback yield (%): 0
Retained earnings: 96450549.45054945
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for STGN.SW — annual report dated 2022-12-31
Total revenue: 345208695.6521739
Gross profit: 194661956.52173913
Operating income: 20177173.913043477
Net income: 12080434.782608695
Capital expenditures: 5288043.478260869
Operating cash flow: 13386956.521739129
Depreciation & amortization: 8400000
Net tangible assets: 185188043.47826087
Owner earnings: 15192391.304347826
Return on net tangible assets (%): 8.2037646810234
Capex to operating income (%): 26.208048268060118
Buffett classification: The Good
Stock price: 47.91304347826087
P/E ratio: 21.667660039589705
Shares outstanding: 5463121
Book value: 187478260.86956525
P/B ratio: 1.3961872314471242
Market cap (USD): 261754754
Debt to equity: 0.007966141001855286
Current ratio: 1.6864205239942607
Quick ratio: 0.9202582770898655
Effective tax rate (%): 38.491338756987105
Interest coverage ratio: 62.925423728813556
COGS to revenue (%): 43.61035542456989
Free cash flow (dilution-adjusted): 5773913.043478261
Buyback yield (%): 0
Retained earnings: 101865217.39130434
Inventory turnover: 1.2008757098885854
Receivables turnover: 3.224775346499467
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.825748192375688
FCF margin (%): 1.6725862112395782
Rule of 40 score: 1.6725862112395782
Financial ratios for STGN.SW — annual report dated 2023-12-31
Total revenue: 486904761.9047619
Gross profit: 276032142.85714287
Operating income: 42640476.190476194
Net income: 29971428.57142857
Capital expenditures: 11203571.42857143
Operating cash flow: 26713095.23809524
Depreciation & amortization: 9291666.666666668
Net tangible assets: 373895238.0952381
Owner earnings: 28059523.80952381
Return on net tangible assets (%): 7.504648615604065
Capex to operating income (%): 26.274498855324136
Buffett classification: The Good
Stock price: 53.17857142857143
P/E ratio: 9.693264024070544
Shares outstanding: 5463121
Book value: 376559523.8095239
P/B ratio: 0.7715140686984286
Market cap (USD): 290520970.3214286
Debt to equity: 0.12772596503430178
Current ratio: 2.2022321792260695
Quick ratio: 0.9747562797012899
Effective tax rate (%): 20.379506641366227
Interest coverage ratio: 23.8945963975984
COGS to revenue (%): 43.30880195599022
Free cash flow (dilution-adjusted): 14630952.38095238
Buyback yield (%): 0
Inventory turnover: 0.7837431252737722
Receivables turnover: 3.98131023070184
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.865559781965013
FCF margin (%): 3.004889975550122
Revenue growth (%): 41.04649391432436
Rule of 40 score: 44.05138388987448
Financial ratios for STGN.SW — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 347826666.6666667
Buffett classification: The Gruesome
Stock price: 38.822222222222216
Shares outstanding: 5463121
Book value: 351233333.3333334
P/B ratio: 0.6038450151529529
Market cap (USD): 212090497.48888886
Debt to equity: 0.19288222454208978
Current ratio: 2.172681334649042
Quick ratio: 1.042404493650983
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for STGN.SW — annual report dated 2024-12-31
Total revenue: 548951111.111111
Gross profit: 312224444.4444444
Operating income: 18552222.22222222
Net income: 13166666.666666666
Capital expenditures: 13484444.444444444
Operating cash flow: 8577777.777777778
Depreciation & amortization: 13738888.888888888
Net tangible assets: 347826666.6666667
Owner earnings: 13421111.111111108
Return on net tangible assets (%): 3.8585630135060875
Capex to operating income (%): 72.68371563753968
Buffett classification: The Good
Stock price: 38.822222222222216
P/E ratio: 16.108139049789028
Shares outstanding: 5463121
Book value: 351233333.3333334
P/B ratio: 0.6038450151529529
Market cap (USD): 212090497.48888886
Debt to equity: 0.19288222454208978
Current ratio: 2.172681334649042
Quick ratio: 1.042404493650983
Effective tax rate (%): 21.068407380270436
Interest coverage ratio: 8.356856856856856
COGS to revenue (%): 43.12345159253203
Free cash flow (dilution-adjusted): -11344444.444444444
Buyback yield (%): 0
Inventory turnover: 1.0220083850603934
Receivables turnover: 4.3409070940306105
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 4.556643524583006
FCF margin (%): -2.0665673526887645
Revenue growth (%): 12.743015484922559
Rule of 40 score: 10.676448132233794
Financial ratios for STGN.SW — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 369930000
Buffett classification: The Gruesome
Stock price: 40.762499999999996
Shares outstanding: 5463121
Book value: 373903750
P/B ratio: 0.5955823384025969
Market cap (USD): 222690469.7625
Debt to equity: 0.1790668052941432
Quick ratio: -1.1109944537009564
Buyback yield (%): 0
Retained earnings: 158858750
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SYMPHONY.NS — annual report dated 2022-03-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 13.749043914018198
Shares outstanding: 68671400
Market cap (USD): 944166094.2371093
Buyback yield (%): 0
Retained earnings: 100346828.432019
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SYMPHONY.NS — annual report dated 2023-03-31
Total revenue: 144194884.28745434
Gross profit: 62920828.258221686
Operating income: 13813641.900121804
Net income: 14180267.96589525
Capital expenditures: 1325213.1546894033
Operating cash flow: 15231425.09135201
Depreciation & amortization: 3221680.876979294
Net tangible assets: 81467722.28989038
Owner earnings: 16076735.688185142
Return on net tangible assets (%): 19.73387157060627
Capex to operating income (%): 9.593510272462744
Buffett classification: The Great
Stock price: 11.861875761266749
P/E ratio: 57.444021305617596
Shares outstanding: 68671400
Book value: 107297198.53836784
P/B ratio: 7.591732368119332
Market cap (USD): 814571615.1522534
Debt to equity: 0.26308022385941815
Current ratio: 1.8048823191015733
Quick ratio: 1.1803106475575897
Effective tax rate (%): 23.733052520731867
Interest coverage ratio: 11.086021505376346
COGS to revenue (%): 56.36403568049736
SG&A to revenue (%): 15.013853223408569
Free cash flow (dilution-adjusted): 13864799.025578564
Buyback yield (%): 0
Retained earnings: 98272838.00243606
Inventory turnover: 2.672139682031156
Receivables turnover: 10.275496918670255
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 11.300656655739013
FCF margin (%): 9.615319637788891
Rule of 40 score: 9.615319637788891
Financial ratios for SYMPHONY.NS — annual report dated 2024-03-31
Total revenue: 138341527.76112244
Gross profit: 66234560.49886078
Operating income: 17882240.076747812
Net income: 17763520.805852022
Capital expenditures: 296198.5849622257
Operating cash flow: 19374025.662549466
Depreciation & amortization: 3097493.704281089
Net tangible assets: 64781148.81880321
Owner earnings: 20564815.925170884
Return on net tangible assets (%): 31.7450621054775
Capex to operating income (%): 1.6563841201716736
Buffett classification: The Great
Stock price: 9.88147792706334
P/E ratio: 38.20047448572174
Shares outstanding: 68671400
Book value: 89820122.31682456
P/B ratio: 7.5548207441422175
Market cap (USD): 678574923.3205374
Debt to equity: 0.22683275256672142
Current ratio: 1.610459967703287
Quick ratio: 1.009845288326301
Effective tax rate (%): 18.137607073777286
Interest coverage ratio: 14.310940499040308
COGS to revenue (%): 52.12243093539522
SG&A to revenue (%): 15.758085347988523
Free cash flow (dilution-adjusted): 18423072.310828637
Buyback yield (%): 3.571531899220549
Retained earnings: 79848902.74613263
Inventory turnover: 2.6075455333911535
Receivables turnover: 6.869298559009169
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 17.88631538544578
FCF margin (%): 13.317094735747165
Revenue growth (%): -4.05933716390601
Rule of 40 score: 9.257757571841156
Financial ratios for SYMPHONY.NS — quarterly report dated 2024-09-30
Capital expenditures: 0
Net tangible assets: 60797897.75441949
Buffett classification: The Gruesome
Stock price: 18.36383182035356
Shares outstanding: 68671400
Book value: 87195413.28236982
P/B ratio: 14.462573121643832
Market cap (USD): 1261070040.4682274
Debt to equity: 0.23561643835616436
Current ratio: 1.2161339421613395
Quick ratio: 0.9254185692541858
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SYMPHONY.NS — quarterly report dated 2024-12-31
Total revenue: 22496794.49819326
Gross profit: 10840424.29187551
Operating income: 3263783.6577689704
Net income: -1165637.0206317753
Capital expenditures: 0
Depreciation & amortization: 349691.10618953255
Owner earnings: -815945.9144422427
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 15.376384193962
Shares outstanding: 68671400
Market cap (USD): 1055917829.537242
COGS to revenue (%): 51.81347150259068
SG&A to revenue (%): 4.66321243523316
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for SYMPHONY.NS — annual report dated 2025-03-31
Total revenue: 183855506.1959317
Gross profit: 90197568.38905774
Operating income: 34506663.54921674
Net income: 24842179.097498246
Capital expenditures: 1946457.7975216273
Operating cash flow: 30256020.575169507
Depreciation & amortization: 2599953.2382511105
Net tangible assets: 64906476.50222118
Owner earnings: 25495674.53822773
Return on net tangible assets (%): 39.28063255344825
Capex to operating income (%): 5.640817156215062
Buffett classification: The Great
Stock price: 12.847940249737427
P/E ratio: 35.51564621618359
Shares outstanding: 68671400
Book value: 88910451.25087677
P/B ratio: 9.92331083301209
Market cap (USD): 882286044.0658187
Debt to equity: 0.18627554106292898
Current ratio: 1.2409058323989484
Quick ratio: 0.7188574159513261
Effective tax rate (%): 23.99585106763475
Interest coverage ratio: 30.027466937945064
COGS to revenue (%): 50.941056781331476
SG&A to revenue (%): 15.991606790869206
Free cash flow (dilution-adjusted): 27545008.183306053
Buyback yield (%): 0.9627571174782601
Retained earnings: 81726677.5777414
Inventory turnover: 2.8208513784725895
Receivables turnover: 11.141258146783791
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 37.36281819217479
FCF margin (%): 14.981878298467604
Revenue growth (%): 32.89972228252338
Rule of 40 score: 47.881600580990984
Financial ratios for SYMPHONY.NS — quarterly report dated 2025-03-31
Total revenue: 57049333.645078324
Gross profit: 26420388.12251578
Operating income: 11924245.966799157
Net income: 9235445.40565817
Capital expenditures: 0
Depreciation & amortization: 584521.8611176057
Net tangible assets: 64906476.50222118
Owner earnings: 9819967.266775776
Return on net tangible assets (%): 15.129410493326848
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 12.847940249737427
P/E ratio: 23.883148167528528
Shares outstanding: 68671400
Book value: 88910451.25087677
P/B ratio: 9.92331083301209
Market cap (USD): 882286044.0658187
Debt to equity: 0.18627554106292898
Current ratio: 1.2409058323989484
Quick ratio: 0.7188574159513261
Effective tax rate (%): 28.18181818181818
Interest coverage ratio: 34
COGS to revenue (%): 53.68852459016394
SG&A to revenue (%): 5.122950819672131
Buyback yield (%): 0
Retained earnings: 81726677.5777414
Inventory turnover: 0.9225027287771558
Receivables turnover: 3.457069991499008
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 12.91122897178517
Revenue growth (%): 153.5887219384078
Rule of 40 score: 153.5887219384078
Financial ratios for SYMPHONY.NS — quarterly report dated 2025-06-30
Total revenue: 29370465.714954365
Gross profit: 14626725.953662533
Operating income: 2808331.3831032063
Net income: 4914579.920430611
Capital expenditures: 0
Depreciation & amortization: 234027.61525860053
Owner earnings: 5148607.535689211
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 12.353966768078633
P/E ratio: 65.33724758992992
Shares outstanding: 68671400
Market cap (USD): 848364193.5174351
Effective tax rate (%): 22
COGS to revenue (%): 50.199203187250994
SG&A to revenue (%): 17.52988047808765
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -48.517425466041054
Rule of 40 score: -48.517425466041054
Financial ratios for SYMPHONY.NS — quarterly report dated 2025-12-31
Total revenue: 19939846.273810852
Gross profit: 9802829.453046676
Operating income: 3007686.309457503
Net income: 2227915.7847833354
Capital expenditures: 0
Depreciation & amortization: 222791.57847833354
Owner earnings: 2450707.363261669
Capex to operating income (%): 0
Buffett classification: The Great
Stock price: 9.732650105826
P/E ratio: 43.93513990467831
Shares outstanding: 68671400
Market cap (USD): 668354708.4772196
Effective tax rate (%): 27.027027027027028
COGS to revenue (%): 50.83798882681564
SG&A to revenue (%): 6.70391061452514
Buyback yield (%): 0
Capitalized R&D asset: 0
Revenue growth (%): -32.10919272669819
Rule of 40 score: -32.10919272669819
Financial ratios for T3T1.DE — annual report dated 2021-12-31
Total revenue: 90781715.125
Gross profit: 17406550.53409091
Operating income: 3044085.2386363633
Net income: 2204379.5681818184
Capital expenditures: 407098.375
Operating cash flow: -195780.7840909091
Depreciation & amortization: 921975.4090909091
Net tangible assets: 19987.875000000004
Owner earnings: 2719256.6022727275
Return on net tangible assets (%): 13604.530758135756
Capex to operating income (%): 13.373422328422214
Buffett classification: The Great
Stock price: 9.886363636363635
P/E ratio: 16.910942298637497
Shares outstanding: 3770662
Book value: 2584266.625
P/B ratio: 14.425034677611167
Market cap (USD): 37278135.68181818
Debt to equity: 0.05351640930414656
Current ratio: 1.5791181720379162
Quick ratio: 1.4677848777142695
Effective tax rate (%): 1.9047752697821785
Interest coverage ratio: 4.616420321269192
COGS to revenue (%): 80.82592897686135
Free cash flow (dilution-adjusted): -617691.0340909091
Buyback yield (%): 0
Retained earnings: -14065409.738636363
Inventory turnover: 43.75267649300202
Receivables turnover: 5.894868353216626
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 22.303702203903704
FCF margin (%): -0.6804134877165431
Rule of 40 score: -0.6804134877165431
Financial ratios for T3T1.DE — annual report dated 2022-12-31
Total revenue: 86114180.91489363
Gross profit: 17393348.80851064
Operating income: 4005796.3404255323
Net income: 2501299.6595744686
Capital expenditures: 361247.4787234043
Operating cash flow: 1534487.35106383
Depreciation & amortization: 896865.8723404256
Net tangible assets: 3114873.7553191492
Owner earnings: 3036918.05319149
Return on net tangible assets (%): 97.49730781241014
Capex to operating income (%): 9.018118946232532
Buffett classification: The Great
Stock price: 10.319148936170212
P/E ratio: 15.555922145120741
Shares outstanding: 3770662
Book value: 4920613.095744681
P/B ratio: 7.907555828684563
Market cap (USD): 38910022.765957445
Debt to equity: 0.02486677240754061
Current ratio: 2.2733981966035297
Quick ratio: 2.105058549098041
Effective tax rate (%): 30.733440899371907
Interest coverage ratio: 14.022071649277708
COGS to revenue (%): 79.80199239693118
Free cash flow (dilution-adjusted): 1171906.765957447
Buyback yield (%): 0
Retained earnings: -1018954.255319149
Inventory turnover: 40.41132725105914
Receivables turnover: 5.166824578842323
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 23.921676290883557
FCF margin (%): 1.3608754719685934
Revenue growth (%): -5.141491547807296
Rule of 40 score: -3.7806160758387026
Financial ratios for T3T1.DE — annual report dated 2023-12-31
Total revenue: 78923042.07777779
Gross profit: 14370319.177777776
Operating income: 969563.7888888889
Net income: 1289732
Capital expenditures: 245653.86666666667
Operating cash flow: 2320343.4
Depreciation & amortization: 937883.5333333333
Net tangible assets: 5160156.855555556
Owner earnings: 1981961.6666666665
Return on net tangible assets (%): 38.40894225013405
Capex to operating income (%): 25.336534788307606
Buffett classification: The Good
Stock price: 5.611111111111111
P/E ratio: 16.404651078242956
Shares outstanding: 3770662
Book value: 6429039.011111114
P/B ratio: 3.2909433910539967
Market cap (USD): 21157603.444444444
Debt to equity: 0
Current ratio: 2.5558639009857016
Quick ratio: 2.4297690978549396
Effective tax rate (%): -49.31453858626323
Interest coverage ratio: 4.126275098495895
COGS to revenue (%): 81.79198520551704
Free cash flow (dilution-adjusted): 2040512.2555555555
Buyback yield (%): 0
Retained earnings: 225490.88888888888
Inventory turnover: 60.011787627660404
Receivables turnover: 5.364203310434106
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 5.782558623288258
FCF margin (%): 2.585445519883348
Revenue growth (%): -8.350702242900992
Rule of 40 score: -5.765256723017644
Financial ratios for T3T1.DE — annual report dated 2024-12-31
Total revenue: 68961926.13541667
Gross profit: 12997093.270833332
Operating income: 1574073.3229166665
Net income: 1449605.5625000002
Capital expenditures: 634953.125
Operating cash flow: 2980858.3333333335
Depreciation & amortization: 716947.9166666667
Net tangible assets: 6703318.177083334
Owner earnings: 1531600.354166667
Return on net tangible assets (%): 22.848391105807217
Capex to operating income (%): 40.33821777904657
Buffett classification: The Good
Stock price: 5.572916666666666
P/E ratio: 14.496070964246634
Shares outstanding: 3770662
Book value: 7476829.635416666
P/B ratio: 2.81049403675434
Market cap (USD): 21013585.104166664
Debt to equity: 2.073071175325265e-06
Current ratio: 3.2873760751451537
Quick ratio: 3.1429284186113153
Effective tax rate (%): 7.762193477378528
Interest coverage ratio: 12.723622934730475
COGS to revenue (%): 81.15323338662022
Free cash flow (dilution-adjusted): 2337758.3333333335
Buyback yield (%): 0
Retained earnings: 1661003.2708333333
Inventory turnover: 65.4517680146094
Receivables turnover: 5.50714484703896
Capitalized R&D asset: 0
ROCI (R&D-adjusted, %): 9.596081097414183
FCF margin (%): 3.3899261002988927
Revenue growth (%): -12.6213025754184
Rule of 40 score: -9.231376475119507
Financial ratios for T3T1.DE — quarterly report dated 2024-12-31
Capital expenditures: 0
Net tangible assets: 6703318.177083334
Buffett classification: The Gruesome
Stock price: 5.572916666666666
Shares outstanding: 3770662
Book value: 7476829.635416666
P/B ratio: 2.81049403675434
Market cap (USD): 21013585.104166664
Debt to equity: 2.073071175325265e-06
Current ratio: 3.2873760751451537
Quick ratio: 3.1429284186113153
Buyback yield (%): 0
Retained earnings: 1661003.2708333333
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for T3T1.DE — quarterly report dated 2025-06-30
Capital expenditures: 0
Net tangible assets: 8532526.282352941
Buffett classification: The Gruesome
Stock price: 6.058823529411765
Shares outstanding: 3770662
Book value: 9260510.988235295
P/B ratio: 2.467010262833495
Market cap (USD): 22845775.647058826
Debt to equity: 0
Current ratio: 3.5001558611555272
Quick ratio: 3.2789629174831196
Buyback yield (%): 0
Retained earnings: 2692048.270588235
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ZYME — annual report dated 2021-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 16.39
Shares outstanding: 73023061
Market cap (USD): 1196847969.79
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ZYME — annual report dated 2022-12-31
Total revenue: 412482000
Operating income: 130486000
Net income: 124341000
Capital expenditures: 8150000
Operating cash flow: 144109000
Depreciation & amortization: 12004000
Net tangible assets: 454557000
Owner earnings: 128195000
Return on net tangible assets (%): 28.202183664534918
Capex to operating income (%): 6.245880784145426
Buffett classification: The Great
Stock price: 7.86
P/E ratio: 4.616025763505199
Shares outstanding: 73023061
Book value: 492956000
P/B ratio: 1.1643255370864742
Market cap (USD): 573961259.46
Debt to equity: 0.05702943061855419
Current ratio: 5.696271895424837
Quick ratio: 5.696271895424837
Effective tax rate (%): 8.054927015395537
COGS to revenue (%): 0
R&D to revenue (%): 50.57093400439292
SG&A to revenue (%): 17.794715890632805
Free cash flow (dilution-adjusted): 126969000
Buyback yield (%): 0
Retained earnings: -558763000
Receivables turnover: 12.349760479041915
Capitalized R&D asset: 208596000
ROCI (R&D-adjusted, %): 35.388133848674535
FCF margin (%): 30.781706838116573
Rule of 40 score: 30.781706838116573
Financial ratios for ZYME — annual report dated 2023-12-31
Total revenue: 76012000
Operating income: -138007000
Net income: -118674000
Capital expenditures: 2474000
Operating cash flow: -118324000
Depreciation & amortization: 17305000
Net tangible assets: 427506000
Owner earnings: -103843000
Return on net tangible assets (%): -24.290419315752292
Buffett classification: The Gruesome
Stock price: 10.39
Shares outstanding: 73023061
Book value: 464806000
P/B ratio: 1.6323145651949416
Market cap (USD): 758709603.7900001
Debt to equity: 0.05749065201395851
Current ratio: 7.405017664042465
Quick ratio: 7.405017664042465
COGS to revenue (%): 0
R&D to revenue (%): 188.9425353891491
SG&A to revenue (%): 92.61695521759722
Free cash flow (dilution-adjusted): -130503000
Buyback yield (%): 0
Retained earnings: -677437000
Receivables turnover: 3.9026544128972636
Capitalized R&D asset: 283378320
ROCI (R&D-adjusted, %): -13.827290923588773
FCF margin (%): -171.6873651528706
Revenue growth (%): -81.57204435587492
Rule of 40 score: -253.25940950874553
Financial ratios for ZYME — quarterly report dated 2024-09-30
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 12.55
Shares outstanding: 73023061
Market cap (USD): 916439415.5500001
Buyback yield (%): 0
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ZYME — annual report dated 2024-12-31
Total revenue: 76304000
Operating income: -119817000
Net income: -122695000
Capital expenditures: 1991000
Operating cash flow: -110058000
Depreciation & amortization: 11193000
Net tangible assets: 322176000
Owner earnings: -113493000
Return on net tangible assets (%): -35.22701877234803
Buffett classification: The Gruesome
Stock price: 14.64
Shares outstanding: 73023061
Book value: 338768000
P/B ratio: 3.155721948472111
Market cap (USD): 1069057613.0400001
Debt to equity: 0.05462735559438908
Current ratio: 3.402847305592679
Quick ratio: 3.402847305592679
COGS to revenue (%): 0
R&D to revenue (%): 176.42718599287062
SG&A to revenue (%): 80.59865799958062
Free cash flow (dilution-adjusted): -130916000
Buyback yield (%): 2.8109804030623002
Retained earnings: -830335000
Receivables turnover: 1.3670877004389501
Capitalized R&D asset: 299682410
ROCI (R&D-adjusted, %): -21.864961995899424
FCF margin (%): -171.57160830362758
Revenue growth (%): 0.3841498710729885
Rule of 40 score: -171.1874584325546
Financial ratios for ZYME — quarterly report dated 2024-12-31
Capital expenditures: 0
Buffett classification: The Gruesome
Stock price: 14.64
Shares outstanding: 73023061
Market cap (USD): 1069057613.0400001
Buyback yield (%): 0.8818046740430703
Capitalized R&D asset: 0
Rule of 40 score: 0
Financial ratios for ZYME — quarterly report dated 2025-03-31
Total revenue: 27110000
Operating income: -25628000
Net income: -22636000
Capital expenditures: 16000
Operating cash flow: -3407000
Depreciation & amortization: 3305000
Net tangible assets: 309589000
Owner earnings: -19347000
Return on net tangible assets (%): -6.249253041936244
Buffett classification: The Gruesome
Stock price: 11.91
Shares outstanding: 73023061
Book value: 324967000
P/B ratio: 2.6762860736936367
Market cap (USD): 869704656.51
Debt to equity: 0.05680576797028621
Current ratio: 4.7074174769211865
Quick ratio: 4.7074174769211865
COGS to revenue (%): 0
R&D to revenue (%): 131.82589450387312
SG&A to revenue (%): 62.70748801180376
Free cash flow (dilution-adjusted): -10147000
Buyback yield (%): 0
Retained earnings: -852971000
Receivables turnover: 1.1023013743189396
Capitalized R&D asset: 35738000
ROCI (R&D-adjusted, %): -0.45503844856121844
FCF margin (%): -37.42899299151605
Rule of 40 score: -37.42899299151605
Financial ratios for ZYME — quarterly report dated 2025-06-30
Total revenue: 48726000
Operating income: -623000
Net income: 2317000
Capital expenditures: 514000
Operating cash flow: 12073000
Depreciation & amortization: 3214000
Net tangible assets: 320445000
Owner earnings: 5017000
Return on net tangible assets (%): 1.5656352884270313
Buffett classification: The Gruesome
Stock price: 12.55
P/E ratio: 98.88211216551576
Shares outstanding: 73023061
Book value: 334506000
P/B ratio: 2.7396800522262685
Market cap (USD): 916439415.5500001
Debt to equity: 0.05583756345177665
Current ratio: 7.69128876422004
Quick ratio: 7.69128876422004
Effective tax rate (%): -8.728296574378227
COGS to revenue (%): 0
R&D to revenue (%): 70.69942125354021
SG&A to revenue (%): 30.579156918277718
Free cash flow (dilution-adjusted): 5318000
Buyback yield (%): 0
Retained earnings: -850654000
Receivables turnover: 18.519954389965793
Capitalized R&D asset: 58393460
ROCI (R&D-adjusted, %): 2.435420647058989
FCF margin (%): 10.914091039691336
Revenue growth (%): 79.73441534489119
Rule of 40 score: 90.64850638458253
Financial ratios for ZYME — quarterly report dated 2025-09-30
Total revenue: 27614000
Operating income: -22064000
Net income: -19602000
Capital expenditures: 410000
Operating cash flow: -31412000
Depreciation & amortization: 2584000
Net tangible assets: 306651000
Owner earnings: -17428000
Return on net tangible assets (%): -5.683333822488758
Buffett classification: The Gruesome
Stock price: 17.08
Shares outstanding: 73023061
Book value: 320064000
P/B ratio: 3.8968265155718855
Market cap (USD): 1247233881.8799999
Debt to equity: 0.0590631873625275
Current ratio: 6.938420188854268
Quick ratio: 6.938420188854268
COGS to revenue (%): 0
R&D to revenue (%): 128.8404432534222
SG&A to revenue (%): 51.061055986094004
Free cash flow (dilution-adjusted): -38733000
Buyback yield (%): 0
Retained earnings: -886472000
Receivables turnover: 0.940787680566912
Capitalized R&D asset: 70452370
ROCI (R&D-adjusted, %): -5.107377196543954
FCF margin (%): -140.26580719924675
Revenue growth (%): -43.32799737306571
Rule of 40 score: -183.59380457231248
Financial ratios for ZYME — annual report dated 2025-12-31
Total revenue: 105965000
Operating income: -92535000
Net income: -81130000
Capital expenditures: 1521000
Operating cash flow: -33005000
Depreciation & amortization: 11110000
Net tangible assets: 255135000
Owner earnings: -71541000
Return on net tangible assets (%): -28.040449173966724
Buffett classification: The Gruesome
Stock price: 26.33
Shares outstanding: 73023061
Book value: 268501000
P/B ratio: 7.160856742172282
Market cap (USD): 1922697196.1299999
Debt to equity: 0.06803326617033084
Current ratio: 5.878515052696252
Quick ratio: 5.878515052696252
COGS to revenue (%): 0
R&D to revenue (%): 129.28797244373143
SG&A to revenue (%): 58.03803142547067
Free cash flow (dilution-adjusted): -63391000
Buyback yield (%): 2.168568201166756
Retained earnings: -953160000
Receivables turnover: 22.847132384648557
Capitalized R&D asset: 274590340
ROCI (R&D-adjusted, %): -16.23158957529795
FCF margin (%): -59.82258292832539
Revenue growth (%): 38.87214300691969
Rule of 40 score: -20.950439921405696
Financial ratios for ZYME — quarterly report dated 2025-12-31
Total revenue: 2515000
Operating income: -44120000
Net income: -41209000
Capital expenditures: 581000
Operating cash flow: -10259000
Depreciation & amortization: 2007000
Net tangible assets: 255135000
Owner earnings: -39783000
Return on net tangible assets (%): -15.592921394555823
Buffett classification: The Gruesome
Stock price: 26.33
Shares outstanding: 73023061
Book value: 268501000
P/B ratio: 7.160856742172282
Market cap (USD): 1922697196.1299999
Debt to equity: 0.06803326617033084
Current ratio: 5.878515052696252
Quick ratio: 5.878515052696252
COGS to revenue (%): 0
R&D to revenue (%): 1241.948310139165
SG&A to revenue (%): 612.3260437375745
Free cash flow (dilution-adjusted): -19829000
Buyback yield (%): 1.3251696653682163
Retained earnings: -953160000
Receivables turnover: 0.5422595946528677
Capitalized R&D asset: 66440430
ROCI (R&D-adjusted, %): -12.58304916319445
FCF margin (%): -788.4294234592446
Revenue growth (%): -90.8923010067357
Rule of 40 score: -879.3217244659803